SIGA Technologies (SIGA) investor relations material

Executive summary

• Revenue for the nine months ended September 30, 2025, was $90.8 million, up from $57.3 million year-over-year, driven by increased U.S. Government and international sales of TPOXX products and higher R&D revenues.

• Net income for the nine months was $28.7 million, more than doubling from $13.5 million in the prior year period.

• Focused on supporting government preparedness for smallpox outbreaks and bioterrorism through rapid deployment of TPOXX, with ongoing engagement in U.S. and international markets.

• Continued progress in late-stage pipeline programs, including post-exposure prophylaxis and pediatric formulations, in collaboration with U.S. government agencies.

• Paid a special cash dividend of $0.60 per share, totaling approximately $43 million, during the period.

Financial highlights

• Product sales and supportive services revenue for the nine months was $85.8 million, up from $53.5 million year-over-year.

• Total revenues for nine months were $90.8 million, compared to $57.3 million in 2024.

• Operating income for the nine months was $33.2 million, up from $12.9 million year-over-year.

• Net income for the nine months ended September 30, 2025, was $28.7 million, with fully diluted EPS of $0.40.

• Cash and cash equivalents increased to $172 million as of September 30, 2025, with no debt.

Outlook and guidance

• Management expects liquidity and capital resources to be sufficient for at least the next twelve months.

• Targeting FDA submission for TPOXX post-exposure prophylaxis indication in 2026, with some potential delays due to government shutdown.

• IND submission for pediatric program targeted by year-end, with phase one trials to follow.

• Expecting multiple international sales in 2026 based on ongoing discussions and stakeholder interest.

• Preparing for 2026 by building on government partnerships and aiming to secure new contracts to underpin future revenues.